Advertisement
News
Advertisement

Edap TMS asks FDA to OK Ablatherm prostate treatment

Fri, 02/01/2013 - 3:52pm
Mass Device

French medical device company Edap TMS asks the FDA for pre-market approval of its Ablatherm treatment for prostate cancer.

Edap TMS

EDAP (NSDQ:EDAP) said it filed for pre-market approval of its Ablatherm-HIFU prostate cancer treatment from the FDA.

The Lyon, France-based medical device company said the high-intensity focused ultrasound device is designed to treat low-risk, localized prostate cancer. The PMA submission is backed by data from Edap's Enlight study, according to a press release.

"We have clearly seen a paradigm shift in prostate cancer, as patients are diagnosed earlier than ever before. Low-risk patients need a middle ground between radical treatment, which is often overly-aggressive, and the anxiety of 'watchful waiting.' Ablatherm-HIFU is well-positioned to address this unmet medical need by providing a unique non-invasive and fully robotic treatment option," CEO Marc Oczachowski said in prepared remarks.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading